X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs WOCKHARDT LTD. - Comparison Results

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA WOCKHARDT LTD. AJANTA PHARMA/
WOCKHARDT LTD.
 
P/E (TTM) x 19.6 -11.6 - View Chart
P/BV x 7.8 2.3 339.3% View Chart
Dividend Yield % 0.8 1.4 53.7%  

Financials

 AJANTA PHARMA   WOCKHARDT LTD.
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
WOCKHARDT LTD.
Mar-17
AJANTA PHARMA/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs1,7201,129 152.3%   
Low Rs1,103627 175.9%   
Sales per share (Unadj.) Rs194.6363.1 53.6%  
Earnings per share (Unadj.) Rs45.2-20.4 -221.2%  
Cash flow per share (Unadj.) Rs50.3-7.0 -721.1%  
Dividends per share (Unadj.) Rs8.0010.00 80.0%  
Dividend yield (eoy) %0.61.1 49.8%  
Book value per share (Unadj.) Rs132.0301.8 43.7%  
Shares outstanding (eoy) m88.77110.55 80.3%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x7.32.4 300.0%   
Avg P/E ratio x31.2-42.9 -72.7%  
P/CF ratio (eoy) x28.1-125.9 -22.3%  
Price / Book Value ratio x10.72.9 367.5%  
Dividend payout %17.7-48.9 -36.2%   
Avg Mkt Cap Rs m125,29997,063 129.1%   
No. of employees `000NA6.8 0.0%   
Total wages/salary Rs m2,5709,665 26.6%   
Avg. sales/employee Rs ThNM5,931.8-  
Avg. wages/employee Rs ThNM1,428.1-  
Avg. net profit/employee Rs ThNM-334.0-  
INCOME DATA
Net Sales Rs m17,27540,146 43.0%  
Other income Rs m1661,143 14.6%   
Total revenues Rs m17,44241,289 42.2%   
Gross profit Rs m5,807128 4,536.9%  
Depreciation Rs m4511,489 30.3%   
Interest Rs m492,253 2.2%   
Profit before tax Rs m5,474-2,472 -221.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,460-211 -691.6%   
Profit after tax Rs m4,014-2,260 -177.6%  
Gross profit margin %33.60.3 10,543.3%  
Effective tax rate %26.78.5 312.2%   
Net profit margin %23.2-5.6 -412.7%  
BALANCE SHEET DATA
Current assets Rs m7,63946,160 16.5%   
Current liabilities Rs m2,71519,258 14.1%   
Net working cap to sales %28.567.0 42.5%  
Current ratio x2.82.4 117.4%  
Inventory Days Days43101 42.9%  
Debtors Days Days7994 83.6%  
Net fixed assets Rs m6,91440,165 17.2%   
Share capital Rs m177553 32.0%   
"Free" reserves Rs m11,44232,814 34.9%   
Net worth Rs m11,72133,367 35.1%   
Long term debt Rs m14931,903 0.5%   
Total assets Rs m14,81489,687 16.5%  
Interest coverage x112.9-0.1 -116,282.5%   
Debt to equity ratio x01.0 1.3%  
Sales to assets ratio x1.20.4 260.5%   
Return on assets %27.40 -319,450.8%  
Return on equity %34.2-6.8 -505.6%  
Return on capital %46.5-0.3 -13,880.6%  
Exports to sales %55.10-   
Imports to sales %6.00-   
Exports (fob) Rs m9,527NA-   
Imports (cif) Rs m1,038NA-   
Fx inflow Rs m10,4229,121 114.3%   
Fx outflow Rs m1,6782,133 78.7%   
Net fx Rs m8,7446,988 125.1%   
CASH FLOW
From Operations Rs m3,264-2,695 -121.1%  
From Investments Rs m-2,093-6,863 30.5%  
From Financial Activity Rs m-1,18612,545 -9.5%  
Net Cashflow Rs m-153,010 -0.5%  

Share Holding

Indian Promoters % 73.8 74.5 99.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 2.3 67.4%  
FIIs % 7.6 7.7 98.7%  
ADR/GDR % 0.0 0.1 -  
Free float % 17.0 15.4 110.4%  
Shareholders   20,968 67,757 30.9%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   VENUS REMEDIES  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  ORCHID PHARMA LTD  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Share Markets Extend Gains; Energy & PSU Stocks Rally(12:30 pm)

Stock markets in India continue to trade higher taking cues from their key Asian counterparts. Sectoral indices are trading in green with stocks in the oil & gas sector.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Beware the 5th year of the Modi Regime(The Honest Truth)

May 22, 2018

2017 was a great year for the market. You were rewarded for taking excessive risk. But Ajit Dayal believes 2018 will be different. You will be rewarded for doing the opposite. Read on to know more...

Beware of Inflated Stock Market Angels(Sector Info)

May 17, 2018

The stock of Vakrangee helps us understand why it's a bad idea to chase high-flying stocks.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


May 28, 2018 02:59 PM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS